Athersys, Inc. (ATHX) stock is popping high in pre-market after the release of positive topline results of the ONE-BRIDGE clinical trial by its partner in Japan, HEALIOS K.K. ATHX stock price saw a surge of 13.64% to reach $1.75 a share as of this writing. The stock went high in the previous trade by 4.05% at closing. Let’s discuss Athersys stock in depth.
What’s Happening?
ATHX, a biotechnology stock that is mainly working in the field of regenerative medicine. Its partner HEALIOS K.K announced positive topline results from one ONE-BRIDGE clinical trial. The trial evaluated the safety and efficacy of MultiStem cell therapy against patients suffering acute respiratory distress syndrome (ARDS).
The ONE-BRIDGE trial consists of two patient cohorts. The first cohort consists of 30 pneumonia-induced ARDS patients in which treatment and registry groups are also present. The second cohort consists of five covid induced ARDS patients. The results were favorable for both cohorts and the study met both primary and secondary endpoints. The primary endpoint of the study was ventilator-free days and the secondary endpoint was the 90-day mortality. These results are similar to ATHX’s placebo-controlled MUST-ARDS study in U.S and U.K. This MultiStem cell therapy is now an orphan regenerative medicine product in Japan to treat ARDS.
ATHX stock’s Ongoing Study:
ATHX stock is currently conducting a double-blind, placebo-controlled, MACoVIA study to evaluate MultiStem in with covid induced ARDS. The United States Food and Drug Administration has given Fast Track and Regenerative Medicine Advanced Therapy to Athersys’s ARDS program.
ATHX stock and HEALIOS K.K MultiStem Partnership:
ATHX stock and HEALIOS K.K has expanded and deepened partnership between them for the optimization and better alignment of their collaboration structure. The main purpose is to increase the reach and commercial success of MultiStem® products in Japan after getting regulatory approvals. The change and new agreement were made by considering Japanese regulatory, manufacturing, and commercial requirements. Moreover, these new agreements also reflect enabling of better optimal investments as well as efforts in manufacturing and commercialization
Conclusion:
The momentum is favorable for ATHX stock in the stock market due to the recent announcements. ATHX stock and, HEALIOS K.K are both striving hard to expand the commercial reach of MultiStem products in Japan. The stock will announce its second-quarter financial results on August 9, 2021, which will further decide its fate.
